Recovery of neurogenic amines in phenylketonuria mice after liver-targeted gene therapy

NeuroReport

Volumn 23, Issue 1, 2012, Pages 30-34

  Yagi, Hiroya ^a,b   Sanechika, Sho ^c   Ichinose, Hiroshi ^c   Sumi Ichinose, Chiho ^d   Mizukami, Hiroaki ^a   Urabe, Masashi ^a   Ozawa, Keiya ^a   Kume, Akihiro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

catecholamine; gene therapy; phenylketonuria; serotonin

Indexed keywords

AMINE; DOPAMINE; NORADRENALIN; PARVOVIRUS VECTOR; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; SEROTONIN; TRYPTOPHAN; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN DYSFUNCTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; HYPERPHENYLALANINEMIA; MOUSE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PHENYLKETONURIA; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BRAIN; CATECHOLAMINES; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; LIVER; MICE; MICE, TRANSGENIC; NEUROTRANSMITTER AGENTS; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; SEROTONIN;

EID: 82555168184     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32834e3a87     Document Type: Article

References (21)

1. Scriver CR, Kaufman S. Hyperphenylalaninemia: Phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed New York: McGraw-Hill. 2001; pp. 1667-1724.
2. McKean CM. The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res 1972; 47:469-476.
3. Güttler F, Lou H. Dietary problems of phenylketonuria: Effect on CNS transmitters and their possible role in behavior and neuropsychological function. J Inherit Metab Dis 1986; 9 (Suppl 2):169-177. (Pubitemid 17189828)
4. Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. Genetics 1993; 134:1205-1210. (Pubitemid 23220041)
5. McDonald JD, Charlton CK. Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 1997; 39:402-405. (Pubitemid 27078708)
6. Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Cali F, Romano V. Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. NeuroReport 2000; 11:1361-1364. (Pubitemid 30262988)
7. Pascucci T, Ventura R, Puglisi-Allegra S, Cabib S. Deficits in brain serotonin synthesis in a genetic mouse model of phenylketonuria. NeuroReport 2002; 13:2561-2564. (Pubitemid 36143563)
8. Mochizuki S, Mizukami H, Ogura T, Kure S, Ichinohe A, Kojima K, et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 2004; 11:1081-1086. (Pubitemid 39023112)
9. Yagi H, Ogura T, Mizukami H, Urabe M, Hamada H, Yoshikawa H, et al. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector. J Gene Med 2011; 13:114-122.
10. Thöny B. Long-term correction of murine phenylketonuria by viral gene transfer: Liver versus muscle. J Inherit Metab Dis 2010; 33:677-680.
11. Kure S, Sato K, Fujii K, Aoki Y, Suzuki Y, Kato S, et al. Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: An implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 2004; 83:150-156. (Pubitemid 39311289)
12. Sumi-Ichinose C, Urano F, Kuroda R, Ohye T, Kojima M, Tazawa M, et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin: A study from 6-pyruvoyltetrahydropterin synthase knockout mice. J Biol Chem 2001; 276:41150-41160.
13. Smith CB, Kang J. Cerebral protein synthesis in a genetic mouse model of phenylketonuria. Proc Natl Acad Sci USA 2000; 97: 11014-11019.
14. Shulkin BL, Betz AL, Koeppe RA, Agranoff BW. Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine. J Neurochem 1995; 64:1252-1257
15. Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 1999; 103:1169-1178. (Pubitemid 29207251)
16. Curtius HC, Niederwiesser A, Viscontini M, Leimbacher W, Wagmann H, Blehova B, et al. Serotonin and dopamine synthesis in phenylketonuria. Adv Exp Med Biol 1981; 133:277-291.
17. Ogawa S, Ichinose H. Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: Comparison with that on tyrosine hydroxylase activity. Neurosci Lett 2006; 401:261-265. (Pubitemid 43729517)
18. Joseph B, Dyer CA. Relationship between myelin production and dopamine synthesis in the PKU mouse brain. J Neurochem 2003; 86:615-626. (Pubitemid 36897442)
19. Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL. Evidence for central nervous system glial cell plasticity in phenylketonuria. J Neuropath Exp Neur 1996; 55:795-814. (Pubitemid 26238582)
20. Embury JE, Charron CE, Martynyuk A, Zori AG, Liu B, Ali SF, et al. PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pahenu2 mice. Brain Res 2007; 1127:136-150. (Pubitemid 44854840)
21. Nathwani AC, Rosales C, McIntosh J, Riddel A, Rustagi P, Galder B, et al. Early clinical trial results following administration of a low dose of a novel self complementary adeno-associated viral vector encoding human factor ix in two subjects with severe haemophilia B. Hum Gene Ther 2010; 21:1362.